Gilead And AbbVie Are Not The Only Ones Re-Thinking CD47 Immunotherapies
Setback Hitting Plans For Big And Small Companies
Executive Summary
CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.
You may also be interested in...
Jefferies Conference Highlights How Biotech’s Rollercoaster Ride Will Continue Into 2024
Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.
Breakdowns In The Breakthrough Lane: When Recipients Of FDA Expedited Designation Fall Short
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
Gilead’s Magrolimab Hit With Third Clinical Hold, This Time In AML
Gilead’s novel immune checkpoint inhibitor candidate, magrolimab, has been placed on a partial clinical hold by the US Food and Drug Administration in acute myeloid leukemia, adding to a spate of recent setbacks for the therapy that are chipping away at investor confidence.